Literature DB >> 2475569

A 15 amino acid fragment of influenza nucleoprotein synthesized in the cytoplasm is presented to class I-restricted cytotoxic T lymphocytes.

K Gould1, J Cossins, J Bastin, G G Brownlee, A Townsend.   

Abstract

A recombinant vaccinia has been designed to express amino acids 366-379 of influenza nucleoprotein, previously shown to be the minimal epitope recognized by a class I-restricted cytotoxic T cell clone. Target cells infected with the recombinant vaccinia virus expressing this peptide are recognized by CTL as efficiently as target cells expressing the complete nucleoprotein. The results imply the existence of a peptide transport system that constitutively passes the products of degraded proteins from the cytoplasm into a membrane-bound compartment of the cell.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2475569      PMCID： PMC2189431          DOI： 10.1084/jem.170.3.1051

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  21 in total

1.  Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum.

Authors:  S Kumar; L H Miller; I A Quakyi; D B Keister; R A Houghten; W L Maloy; B Moss; J A Berzofsky; M F Good
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

2.  Class I MHC-restricted recognition of cells expressing a gene encoding a 41 amino acid product of the influenza hemagglutinin.

Authors:  M T Sweetser; V L Braciale; T J Braciale
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

3.  HLA-A2 peptides can regulate cytolysis by human allogeneic T lymphocytes.

Authors:  C Clayberger; P Parham; J Rothbard; D S Ludwig; G K Schoolnik; A M Krensky
Journal:  Nature       Date:  1987 Dec 24-31       Impact factor: 49.962

4.  Introduction of soluble protein into the class I pathway of antigen processing and presentation.

Authors:  M W Moore; F R Carbone; M J Bevan
Journal:  Cell       Date:  1988-09-09       Impact factor: 41.582

5.  The sequence of the nucleoprotein gene of human influenza A virus, strain A/NT/60/68.

Authors:  J A Huddleston; G G Brownlee
Journal:  Nucleic Acids Res       Date:  1982-02-11       Impact factor: 16.971

6.  Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses.

Authors:  G L Smith; J Z Levin; P Palese; B Moss
Journal:  Virology       Date:  1987-10       Impact factor: 3.616

7.  Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89.

Authors:  M Del Val; H Volkmer; J B Rothbard; S Jonjić; M Messerle; J Schickedanz; M J Reddehase; U H Koszinowski
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

8.  Recognition by cytotoxic T lymphocytes of cells expressing fragments of the SV40 tumor antigen.

Authors:  L R Gooding; K A O'Connell
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

9.  Cytotoxic T lymphocyte recognition of the influenza hemagglutinin gene product expressed by DNA-mediated gene transfer.

Authors:  T J Braciale; V L Braciale; T J Henkel; J Sambrook; M J Gething
Journal:  J Exp Med       Date:  1984-02-01       Impact factor: 14.307

10.  Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen.

Authors:  A Townsend; J Bastin; K Gould; G Brownlee; M Andrew; B Coupar; D Boyle; S Chan; G Smith
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307
View more
  15 in total

1.  Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope.

Authors:  M Del Val; H J Schlicht; H Volkmer; M Messerle; M J Reddehase; U H Koszinowski
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

2.  Do we need a pepton hypothesis?

Authors:  K F Lindahl
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

3.  A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge.

Authors:  J L Whitton; N Sheng; M B Oldstone; T A McKee
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

4.  A lung-specific neo-antigen elicits specific CD8+ T cell tolerance with preserved CD4+ T cell reactivity. Implications for immune-mediated lung disease.

Authors:  R I Enelow; M H Stoler; A Srikiatkhachorn; C Kerlakian; S Agersborg; J A Whitsett; T J Braciale
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

Review 5.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

6.  Characterization of two distinct major histocompatibility complex class I Kk-restricted T-cell epitopes within the influenza A/PR/8/34 virus hemagglutinin.

Authors:  K G Gould; H Scotney; G G Brownlee
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

7.  Assessment of the specificity of cytotoxic T lymphocytes for the nucleoprotein of Pichinde virus using recombinant vaccinia viruses.

Authors:  D Y Ozols; D G Harnish; W E Rawls; K L Rosenthal
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

8.  Simian virus 40 T antigen as a carrier for the expression of cytotoxic T-lymphocyte recognition epitopes.

Authors:  T M Fu; R H Bonneau; M J Tevethia; S S Tevethia
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.

Authors:  N P Restifo; F Esquivel; A L Asher; H Stötter; R J Barth; J R Bennink; J J Mulé; J W Yewdell; S A Rosenberg
Journal:  J Immunol       Date:  1991-08-15       Impact factor: 5.422

10.  Functional analysis of amino acid residues encompassing and surrounding two neighboring H-2Db-restricted cytotoxic T-lymphocyte epitopes in simian virus 40 tumor antigen.

Authors:  J D Lippolis; L M Mylin; D T Simmons; S S Tevethia
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.